日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.

双重葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1受体激动剂替拉帕肽可改善2型糖尿病患者的心血管风险生物标志物:一项事后分析

Wilson Jonathan M, Lin Yanzhu, Luo M Jane, Considine Gary, Cox Amy L, Bowsman Lenden M, Robins Deborah A, Haupt Axel, Duffin Kevin L, Ruotolo Giacomo

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

双重GIP和GLP-1受体激动剂替尔泽帕肽可改善2型糖尿病患者的β细胞功能和胰岛素敏感性

Thomas, Melissa K; Nikooienejad, Amir; Bray, Ross; Cui, Xuewei; Wilson, Jonathan; Duffin, Kevin; Milicevic, Zvonko; Haupt, Axel; Robins, Deborah A

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens

替泽帕肽(一种双重葡萄糖依赖性促胰岛素肽和胰高血糖素样肽-1受体激动剂)在2型糖尿病患者中的疗效和耐受性:一项为期12周的随机、双盲、安慰剂对照研究,旨在评估不同的剂量递增方案

Frias, Juan Pablo; Nauck, Michael A; Van, Joanna; Benson, Charles; Bray, Ross; Cui, Xuewei; Milicevic, Zvonko; Urva, Shweta; Haupt, Axel; Robins, Deborah A

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

替泽帕肽是一种双重葡萄糖依赖性促胰岛素肽和胰高血糖素样肽-1受体激动剂,可改善2型糖尿病患者与胰岛素抵抗和心血管风险相关的脂蛋白生物标志物。

Wilson, Jonathan M; Nikooienejad, Amir; Robins, Deborah A; Roell, William C; Riesmeyer, Jeffrey S; Haupt, Axel; Duffin, Kevin L; Taskinen, Marja-Riitta; Ruotolo, Giacomo